Evidence map›Paper›PMID 33033184›Full record

ArticleJournal for immunotherapy of cancer2020

Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis.

Sienna M Durbin, Meghan J Mooradian, Florian Johannes Fintelmann, Leyre Zubiri, Donald F Chute, Avinash Kambadakone, Nisanard Pisuchpen, Kerry L Reynolds, Michael Dougan

Open access · goldAbstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026
    Review
  2. Article
  3. Article
  4. Immune checkpoint inhibitor-induced diarrhea and colitis: an overview.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Review
  5. Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management.International journal of molecular sciences · 2023
    Review
  6. Review
  7. Update on Immune Checkpoint Inhibitor Enterocolitis.Current gastroenterology reports · 2022
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Sienna M DurbinHarvard Medical School, Boston, Massachusetts, USA.
Meghan J MooradianHarvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-8289-8015
Florian Johannes FintelmannHarvard Medical School, Boston, Massachusetts, USA.
Leyre ZubiriCancer Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Donald F ChuteCancer Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Avinash KambadakoneHarvard Medical School, Boston, Massachusetts, USA.
Nisanard PisuchpenDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Kerry L ReynoldsHarvard Medical School, Boston, Massachusetts, USA mldougan@partners.org kreynolds7@mgh.harvard.edu.
Michael DouganHarvard Medical School, Boston, Massachusetts, USA mldougan@partners.org kreynolds7@mgh.harvard.edu.ORCID 0000-0001-9266-2009
Harvard University · USMassachusetts General Hospital · USThai Red Cross Society · TH

Funding

Regulation of brown fat metabolism by the immune receptor PD-L1K08DK114563 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI DOUGAN, MICHAEL LAWRENCE · 2017 to 2021
$868k
NIDDK NIH HHS K08 DK114563
6 · The paper itself

Abstract

BACKGROUND AND

aimsImmune checkpoint inhibitor (ICI) enterocolitis is a common immune-related adverse event and can be fatal, especially when not diagnosed and treated promptly. The current gold standard for diagnosis is endoscopy with biopsy, but CT scan is a possible alternative. The primary objective of this study is to identify the diagnostic performance of CT in the evaluation of ICI enterocolitis.

methodsWith institutional review board approval, we conducted a retrospective cohort study of patients who received ICI therapy between 2015 and 2019 across a healthcare system. Patients were included if they underwent both abdominal CT and endoscopy with biopsy within 3 days. The radiological and pathological diagnoses, as well as clinical characteristics, were extracted from the electronic medical record. We calculated the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of CT for diagnosing ICI enterocolitis when compared with tissue diagnosis.

resultsOf the 4474 patients screened, 138 met inclusion criteria. Most common tumor types were melanoma (37%) and lung cancer (19%). Seventy-four per cent were treated with antiprogrammed cell death (PD-1)/PD-L1 therapy. Thirty-nine per cent had signs of enterocolitis on CT scan and 58% had biopsy-proven ICI enterocolitis. Sensitivity and specificity of CT were 50% and 74%, respectively. PPV was 73% and NPV was 52%. Of those with confirmed ICI enterocolitis, 70% had grade 3 or higher symptoms, 91% received steroids and 40% received infliximab.

conclusionThe performance of CT scan for diagnosis of ICI enterocolitis is moderate to poor and does not replace endoscopy with biopsy.

Indexed as

AgedEnterocolitisFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedRetrospective StudiesTomography, X-Ray ComputedImmune Checkpoint Inhibitorsautoimmunityimmunotherapyinflammation

Identifiers

PMID33033184
PMCPMC7545618
OpenAlexW3091937423

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.